What are the contraindications of antilipemic therapy with a HMG coenzyme A reductase inhibitor?

The contraindication of antilipemic therapy with a HMG coenzyme A reductase inhibitor, commonly known as statins, is primarily linked to liver disease. Statins are metabolized in the liver, and their use in patients with existing liver dysfunction can exacerbate liver problems or lead to hepatotoxicity. This is particularly concerning because statins can cause elevations in liver enzymes and potentially progress to serious liver injury in susceptible individuals. Therefore, a history of liver disease warrants careful evaluation and consideration before initiating therapy with statins to avoid these potential complications.

In this context, the other choices do not have the same level of concern when it comes to the use of HMG coenzyme A reductase inhibitors. While asthma, hypertension, and osteoporosis may require monitoring or management in relation to broader health considerations, they do not establish a direct contraindication for statin therapy as liver disease does. Thus, patients with these conditions can often still be prescribed statins with caution and appropriate monitoring.